Biznes · 26.03.20261 min czytania
Elite Laboratories, Inc., et al.; Withdrawal of Approval of 72 Abbreviated New Drug Applications; Correction
Automatyczne tłumaczenie lokalne · Oryginalny język źródła
Streszczenie
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on September 24, 2025 (90 FR 183), appearing on page 45942 in FR Doc. 2025-18453. The document announced the withdrawal of approval of 72 abbreviated new drug applications (ANDAs) from multiple applicants, withdrawn as of October 23, 2025. The document indicated that FDA was withdrawing approval of the ANDA 070631 for valproic acid, capsule, 250 milligrams, held by Upsher-Smith Laboratories, LLC, 6701 Evenstad Dr., Maple Grove, MN 55369. Before FDA withdrew the approval of this ANDA, Upsher-Smith Laboratories, LLC, 6701 Evenstad Dr., Maple Grove, MN 55369, informed FDA that they did not want the approval of the ANDA withdrawn. Because Upsher-Smith Laboratories, LLC, timely requested that approval of the ANDA not be withdrawn, the approval is still in effect. This notice corrects this error.